Kane Biotech Announces First Quarter 2018 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
151
Kane Biotech Announces First Quarter 2018 Financial Results, Granting of Options and Investor Relations Improvements

WINNIPEG, Manitoba, May 17, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE ) (OTCQB:KNBIF) (the “Corporation” or “Kane Biotech”) announces its First Quarter 2018 Financial Results, granting of options and investor relations improvements to its website.

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. 

Key Highlights of Kane Biotech include the following:

  • Royalty-based revenue model specializing on large markets for biofilm prevention and dispersion solutions that are implicated in 80% of animal and human bacterial infections
  • Strong patent portfolio of anti-biofilm technologies with 75 patents and patents pending
  • First commercial licensing and distribution agreement signed (2017)
  • Several anti-biofilm applications in development for large market opportunities

Targeted company milestones for 2018 include the following:

  • Uplist to OTCQB Venture Market (January 2018)
  • Retain investor relations counsel (February 2018)
  • File lawsuit against Nestlé to defend Kane Biotech’s intellectual property (February 2018)
  • Existing license expansion for companion animal veterinary market in terms of geography and product applications
  • Complete additional trials and achieve International standard of canine oral care efficacy
  • Launch DispersinB ® based products with Dechra
  • Execute new technology license and distribution agreements
  • Initiate clinical trials for technologies treating human chronic inflammatory skin disorders

First Quarter 2018 Financial Highlights:

Total Revenue:

  • For the quarter ended March 31, 2018 were $93,210, a decrease of 88% compared to $784,900 for the quarter ended March 31, 2017. 

License and Royalty Revenue:

  • For the quarter ended March 31, 2018 were $13,097, a decrease of 98% compared to $670,725 for the quarter ended March 31, 2017.
    • Note : License and Royalty Revenue in Q1, 2017 included a $500,000 USD initial license payment from Dechra.

Product and Services Revenue:

  • For the quarter ended March 31, 2018 were $80,113, a decrease of 30% compared to $114,175 for the three months ended March 31, 2017. 
    • Note : Product and Service Revenues in Q1 2018 no longer included StrixNB in North America as this technology was licensed to Dechra for the North American veterinary channel.  StrixNB revenue in Q1 2017 was $46,274.

Gross Profit % (of Product Sales):

  • For the quarter ended March 31, 2018 was 51%, a decrease of 25% compared to 68% for the quarter ended March 31, 2017.

Total Operating Expenses:

  • For the quarter ended March 31, 2018 were $942,890, a decrease of 2% compared to $959,135 for the quarter ended March 31, 2017.

Loss:

  • For the quarter ended March 31, 2018 was ($889,796), an increase of 274% compared to ($237,692) for the quarter ended March 31, 2017.

Select Income Statement Information:

Kane Biotech Inc.     Q1 2018
TSX-V:KNE / OTCQB:KNBIF Q1 2018 Q1 2017 vs Q1 2017
Total Revenue $ 93,210   $ 784,900   -88 %
License and Royalty Revenue* $ 13,097   $ 670,725   -98 %
Product and Services Revenue** $ 80,113   $ 114,175   -30 %
Gross Profit $ (Product and Services) $ 40,729   $ 77,290   -47 %
Gross Profit % (Product and Services)   51 %   68 % -25 %
Total Operating Expenses $ 942,890   $ 959,135   -2 %
General and Administration $ 709,295   $ 750,384   -5 %
Research $ 233,595   $ 208,751   12 %
Loss for the Period $ (889,796 ) $ (237,692 ) 274 %
Loss per Share (Post Consolidation) $ (0.011 ) $ (0.005 ) 120 %
*  License and Royalty Revenue in Q1, 2017 included a $500,000 USD initial license payment from Dechra.
** Product and Services Revenue in Q1, 2018 included only a small amount of international StrixNB sales as this technology was licensed to Dechra for the North American veterinary channel in Q1, 2017.
 

Select Cash Flow Information:

Kane Biotech Inc.     Q1 2017
TSX-V:KNE / OTCQB:KNBIF Q1 2018 Q1 2017 vs Q1 2016
Cash, end of period $ 1,244,828   $ 579,553   115 %
Cash, beginning of period $ 1,975,723   $ 739,568   167 %
Operating activities $ (712,617 ) $ (72,621 ) 881 %
Financing activities   0   $ (11,877 ) -  
Investing activites $ (18,278 ) $ (99,271 ) -82 %
                 

Detailed financial information about Kane Biotech can be found in its March 31, 2018 Financial Statements and Management Discussion and Analysis on SEDAR and on the Company’s website.  All amounts referenced herein are in Canadian dollars.

The Company’s First Quarter 2018 Earnings Conference Call and Business Update is scheduled on Friday, May 18, 2018 at 8:30am E.T. to discuss its financial results for the first quarter 2018, in conjunction with the filing of its Financial Statements for the first quarter ended March 31, 2018.

Mark Ahrens-Townsend, President and Chief Executive Officer, and Ray Dupuis, Chief Financial Officer of Kane, will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the earnings announcement part of the call.

To participate in the call, please dial +1 877-268-9044 (toll-free) in the U.S. and Canada. The conference ID number is 9749257.

Event:   Kane Biotech Q1 2018 Earnings & Business Update Conference Call
Date:   Friday, May 18, 2018
Time:   8:30am E.T.
U.S. & Canada Dial-in:   877-268-9044 (toll free in Canada and the U.S.)
Conference ID:   9749257
Webcast Link:   https://edge.media-server.com/m6/p/qwnb3dc7
     

A live audio webcast of the conference call will also be available on the investor relations page of Kane’s corporate website at www.kanebiotech.com . In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Kane’s website.

Granting of Options:

Kane Biotech has granted an aggregate of 1,325,000 stock options at an exercise price of $0.20 per common share to directors, management and employees of the Corporation. The options pursuant to the Corporation's stock option plan are subject to TSX Venture Exchange acceptance. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to resale restriction for a period of four months from the date of the grant.

Investor Relations Website Enhancements:

Several enhancements have been made to the Kane Biotech website, especially in the “Investor” tab to provide shareholders, potential investors and analysts all of the relevant information about Kane Biotech in one place.

For more information, please visit www.kanebiotech.com or contact:

Mark Ahrens-Townsend President & CEO Kane Biotech Inc. +1 (204) 477-7592 ir@kanebiotech.com
   
Tirth Patel Vice President - Investor Relations Edison Advisors +1 (646) 653-7035 tpatel@edisongroup.com
   

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com . The Company cautions that the foregoing list of factors that may affect future results is not exhaustive. 

These risks and uncertainties should be considered carefully undue reliance should not be placed on the forward-looking statements.  Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot provide assurance that actual results will be consistent with these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading